BioNotebook: Kite IPO catches strong breeze; plus Endocyte, Merrimack, Aastrom, Nektar, Horizon, Acorda, Ariad
This article was originally published in Scrip
Kite ends busy IPO week strong; Endocyte, Merck end vintafolide agreement; Merrimack, Sanofi end MM-121 deal; Aastrom strategy includes layoffs; Nektar benefits from Ophthotech/Novartis pact; Horizon secures acquisition debt; and Acorda, Ariad sell notes.
You may also be interested in...
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.
Despite positive Phase III results in Lennox-Gastaut syndrome, the effect of the company’s low-dose fenfluramine on serious seizures may not be as good as seen with GW Pharma’s Epidiolex.